Amarantus Bioscience Holdings Inc (AMBS)

[Skeetz99]

LymPro update from Jason Napodono's recent blog. Dont let the manipulators here try to persuade you into selling your shares...here are the facts regarding the recently released LymPro data (a reality that some here conveniently leave out with when trying to convince everyone that LymPro doesnt work well):

JN blog info:
"We also believe that the data presented at AAIC and C4CT represents a “floor” in terms of LymPro accuracy. This is because the data presented at these events was from V1 and not designed for the multivariable analysis which Amarantus is moving forward on with V2. As the company fine-tunes the parameters of the test by tweaking things like cell lines and stimulations times, we believe the overall accuracy will trend higher. We are hoping to see the results from the LP-002 study in the next several weeks.

From a commercial product standpoint, it is not desirable to manipulate the test to increase one aspect of the analysis because overall accuracy is the balance of both Sensitivity and Specificity. But for enrollment in a clinical trial, when a big pharmaceutical company is clearly more interested in finding "True Positive" patients than worried about missing a "True Negative", fine tuning the analysis to enhance enrollment is a powerful tool under CLIA. Yet, Amarantus believes that even with 80% accuracy, LymPro offers meaningful utility for research only use (ROU) and clinical trial screening".